Patients with otosclerosis who are currently pregnant or breastfeeding (lactating) require a modified treatment approach. Standard pharmacological management must be carefully reconsidered in this population given the physiological changes and the need to safeguard both mother and child.
Sodium fluoride can pass easily through the placenta and is secreted into breast milk. Pregnant and breastfeeding women should eliminate or decrease the dose of sodium fluoride, making dose adjustment a central part of management in this setting.
The approach in this scenario centres on modifying sodium fluoride use. The specific course of action — including whether to reduce or fully withhold, and the clinical considerations that guide that decision — is detailed in the full structured protocol.
DOI: 10.1016/j.otc.2017.11.006
View source ↗